Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
The purpose of the study is to evaluate the effectiveness and safety of fedratinib as maintenance therapy in participants with myeloproliferative neoplasms (MPNs) after allogeneic hematopoietic cell transplant (HCT).
Epistemonikos ID: ef43f015c1c64374294eaa9eb241d44dcd2c637b
First added on: May 09, 2024